Latest Regulatory Approval News

Platinum Asia Investments Limited has refined the payout figure for its final special dividend, enhancing precision for shareholders ahead of the September payment date.

PolyNovo Limited reported a robust 28.9% increase in group sales to A$118.6 million for FY25, alongside a 151% surge in net profit after tax to A$13.2 million, driven by strong U.S. growth and key regulatory approvals.

InhaleRx Limited reported a widening half-year loss as it accelerates clinical trials for inhaled drug-device therapies, supported by a substantial $38.5 million funding facility.

Karoon Energy has upgraded its 2025 production guidance even as a key downhole pump failure at its Baúna Project in Brazil restricts output. The company is planning a rig-based intervention to restore full capacity by mid-2026.

Dome Gold Mines has announced a $5 million Share Purchase Plan at a 6.25% discount to fund critical milestones for its Sigatoka Sands Project in Fiji, aiming to secure a mining licence and commence operations.

Noxopharm has successfully completed the third dosing phase of its HERACLES trial for SOF-SKN™, confirming safety and moving forward to the highest dose cohort in this pioneering autoimmune drug study.

An independent in vivo study from the University of South Florida reveals ArtemiC™ significantly boosts survival and reduces inflammation in a severe viral model, reinforcing its promise as a novel immunomodulatory therapy.

Alligator Energy has secured final regulatory approval to begin its in-situ Field Recovery Trial at the Samphire Uranium Project, advancing the development of its recently upgraded Blackbush Deposit resource.

Santos Limited reports a 31% drop in net profit for H1 2025 despite increased sales volumes and progress on key projects, while receiving a non-binding acquisition proposal from an Abu Dhabi-led consortium.

Haranga Resources has secured regulatory approvals and begun underground works at its Lincoln Gold Project, setting the stage for a maiden drilling campaign aimed at upgrading a significant historical gold resource to JORC standards.

LTR Pharma’s SPONTAN nasal spray has achieved unanimous patient satisfaction in treating erectile dysfunction after prostate surgery, signaling a promising shift in therapy preferences.

Decidr AI Industries has agreed to acquire the remaining 49% stake in Decidr.ai, issuing 78.4 million shares to complete full ownership and accelerate its AI platform integration.